Angiogenesis plays a major role in supplying nutrients and oxygen in embryogenesis, wound healing and placental implantation for the delivery of nutrients and the removal of waste products. In pathologic conditions, such as tumor growth, diabetic retinopathy, psoriasis and rheumatoid arthritis, the angiogenic response plays a role in disease progression. As a result, angiogenesis has become a prime target for novel therapies in a variety of medical indications.

The study and development of anti-angiogenic therapies depends on reliable and reproducible stimulation models of neovascular response. Charles River has several experimental techniques that allow an effective examination of short-term neovascularization and angiogenic response to bFGF, VEGF or other angiogenic stimuli:

Corneal Micropocket Assay

  • Hydron pellet prepared with growth factors chosen for specific study requirements
  • Surgical implantation of pellet into a corneal micropocket
  • Corneal neovascularization measured using slit-lamp microscope
  • Short-term study with rapid turnaround times

In Vivo Screens Using Angiogenic-Dependent
Tumor Growth

  • Bevacizumab can be used as a positive control.

Metronomic Dosing1

  • Long-term, low-level dosing of cytotoxics or other agents of interest to inhibit growth and development of vascular endothelium while avoiding whole-animal toxicity
  • Metronomic dose determination for use in efficacy study
  • Studies can last up to 90 days

1. Browder, 2000; Cancer Research 60:1878